Overall Survival with Osimertinib in Untreated, EGFR -Mutated Advanced NSCLC

Cited by (1,002)

Items 401–500 of 1,002

1. Oleocanthal as a Multifunctional Anti-Cancer Agent: Mechanistic Insights, Advanced Delivery Strategies, and Synergies for Precision Oncology
   Shirin Jannati, Adiba Patel, Rajashree Patnaik, Yajnavalka Banerjee · 2025 · International Journal of Molecular Sciences
2. Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis
   Shuo Zhang, Zhen Chen, Puyu Shi, Songqing Fan, Yong He, Qiming Wang, Yixiang Li, Suresh S. Ramalingam, Taofeek Kunle Owonikoko, Shi‐Yong Sun · 2021 · Theranostics
3. Favorable tumor biology in locally advanced pancreatic cancer—beyond CA19-9
   Benedict Kinny‐Köster, Joseph R. Habib, Christopher Lee Wolfgang, Jin Peng He, Ammar A. Javed · 2021 · Journal of Gastrointestinal Oncology
4. Precision Medicine in Oncology: A Review of Multi-Tumor Actionable Molecular Targets with an Emphasis on Non-Small Cell Lung Cancer
   Matthew K. Stein, Oluchukwu Oluoha, Kruti Patel, Ari M. Vanderwalde · 2021 · Journal of Personalized Medicine
5. Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both
   Guangzhi Ma, Yunfu Deng, Luxi Qian, Karin A. Vallega, Guojing Zhang, Xingming Deng, Taofeek Kunle Owonikoko, Suresh S. Ramalingam, Douglas D. Fang, Yifan Zhai et al. · 2022 · Oncogene
6. Osimertinib and anti-HER3 combination therapy engages immune dependent tumor toxicity via STING activation in trans
   Jose Miguel Vicencio, Rachel Evans, R. Green, Zhengwen An, Jinhai Deng, Conor A. Treacy, Rami Mustapha, James Monypenny, Cristóbal Costoya, Katherine Lawler et al. · 2022 · Cell Death and Disease
7. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study
   Yuankai Shi, Shiman Wu, Ke Wang, Shundong Cang, Wenxiu Yao, Yun Fan, Lin Wu, Meijuan Huang, Xingya Li, Yueyin Pan et al. · 2022 · Journal of Thoracic Oncology
8. Targeting tumor-associated macrophages with STING agonism improves the antitumor efficacy of osimertinib in a mouse model of EGFR-mutant lung cancer
   Ziying Lin, Qiwei Wang, Tao Jiang, Weihua Wang, Jean J. Zhao · 2023 · Frontiers in Immunology
9. Phase 2 study of osimertinib in combination with platinum and pemetrexed in patients with previously untreated EGFR-mutated advanced non-squamous non-small cell lung cancer: The OPAL Study
   Ryota Saito, Shunichi Sugawara, Ryo Ko, Koichi Azuma, Ryo Morita, Makoto Maemondo, Satoshi Oizumi, Kazuhisa Takahashi, Hiroshi Kagamu, Yukari Tsubata et al. · 2023 · European Journal of Cancer
10. Overcoming AZD9291 Resistance and Metastasis of NSCLC via Ferroptosis and Multitarget Interference by Nanocatalytic Sensitizer Plus AHP‐DRI‐12
    Liting Wang, Hao Fu, Liwei Song, Zhihua Wu, Jian Yu, Qianqian Guo, Chuanrong Chen, Xupeng Yang, Jiali Zhang, Quan Wang et al. · 2022 · Small
11. Strategies to overcome myeloid cell induced immune suppression in the tumor microenvironment
    Jennifer H. Cao, Lyndah Chow, STEVEN W. DOW · 2023 · Frontiers in Oncology
12. Aspiring toward equitable benefits from genomic advances to individuals of ancestrally diverse backgrounds
    Ying Wang, Yixuan He, Yue Shi, David C. Qian, Kathryn J. Gray, Robert A. Winn, Alicia R. Martin · 2024 · The American Journal of Human Genetics
13. Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study
    Shun Lü, M-J. Ahn, Thanyanan Reungwetwattana, Mustafa Özgüroğlu, Terufumi Kato, James Chih‐Hsin Yang, Meijuan Huang, F. Fujiki, T. Inoue, L-V Quang et al. · 2024 · Annals of Oncology
14. Selpercatinib in RET Fusion–Positive Non–Small Cell Lung Cancer: Final Safety and Efficacy, Including Overall Survival, From the LIBRETTO-001 Phase I/II Trial
    Oliver Pascal Gautschi, Keunchil Park, Benjamin Solomon, Pascale Tomasini, Herbert Ho-Fung Loong, Filippo de Braud, Kōichi Goto, Patrick M. Peterson, Scott S. Barker, Katherine Liming et al. · 2025 · Journal of Clinical Oncology
15. Genomics-guided pre-clinical development of cancer therapies
    Hayley E. Francies, Ultan McDermott, Mathew J. Garnett · 2020 · Nature Cancer
16. Refined Stratification Based on Baseline Concomitant Mutations and Longitudinal Circulating Tumor DNA Monitoring in Advanced EGFR-Mutant Lung Adenocarcinoma Under Gefitinib Treatment
    Jianchun Duan, Jiachen Xu, Zhijie Wang, Hua Bai, Ying Cheng, Tongtong An, Hongjun Gao, Kai Wang, Qing Hua Zhou, Yanping Hu et al. · 2020 · Journal of Thoracic Oncology
17. Targeting G1/S phase cell-cycle genomic alterations and accompanying co-alterations with individualized CDK4/6 inhibitor–based regimens
    Shumei Kato, Ryosuke Okamura, Jacob J. Adashek, Noor Khafifah Khalid, Suzanna Lee, Van Thomas Nguyen, Jason Keith Sicklick, Razelle Kurzrock · 2021 · JCI Insight
18. Detection of EGFR Mutations in Plasma cfDNA and Paired CTCs of NSCLC Patients before and after Osimertinib Therapy Using Crystal Digital PCR
    Aliki Ntzifa, Athanasios Panayotis Kotsakis, Vassilis Georgoulias, Evi S. Lianidou · 2021 · Cancers
19. Tumor immune microenvironment in epidermal growth factor receptor-mutated non-small cell lung cancer before and after epidermal growth factor receptor tyrosine kinase inhibitor treatment: a narrative review
    Lihui Liu, Chao Wang, Sini Li, Hua Bai, Jie Wang · 2021 · Translational Lung Cancer Research
20. Rapid genomic profiling of circulating tumor DNA in non-small cell lung cancer using Oncomine Precision Assay with GenexusTM integrated sequencer
    Siew‐Kee Low, Ryo Ariyasu, Ken Uchibori, Rie Hayashi, Ting Chan, Yoon Ming Chin, Takahiro Akita, Yuhei Harutani, Ayu Kiritani, Ryosuke Tsugitomi et al. · 2022 · Translational Lung Cancer Research
21. Targeting the EGF receptor family in non-small cell lung cancer—increased complexity and future perspectives
    Tobias Boch, Jens Köhler, Melanie Janning, Sonja Loges · 2022 · Cancer Biology and Medicine
22. A phosphoglycerate mutase 1 allosteric inhibitor overcomes drug resistance to EGFR-targeted therapy via disrupting IL-6/JAK2/STAT3 signaling pathway in lung adenocarcinoma
    Qian Liang, Miaomiao Gong, Jing-Hua Zou, Mingyu Luo, Lu-lu Jiang, Cheng Wang, Ning-Xiang Shen, Mo-cong Zhang, Lu Xu, Hui-min Lei et al. · 2023 · Drug Resistance Updates
23. Three-Year Safety, Tolerability, and Health-Related Quality of Life Outcomes of Adjuvant Osimertinib in Patients With Resected Stage IB to IIIA EGFR-Mutated NSCLC: Updated Analysis From the Phase 3 ADAURA Trial
    Thomas John, Christian Grohé, Jonathan Wade Goldman, Frances A. Shepherd, Filippo de Marinis, Terufumi Kato, Qun Wang, Wu‐Chou Su, Jin‐Hyuk Choi, Virote Sriuranpong et al. · 2023 · Journal of Thoracic Oncology
24. SH-1028, An Irreversible Third-Generation EGFR TKI, Overcomes T790M-Mediated Resistance in Non-Small Cell Lung Cancer
    Han, Luwei, Zhang, Xiaomeng, Wang, Zhiqiang, Zhang, Xian, Zhao, Liwen, Fu, Wei, Liang, Xiaobo, Zhang, Zhibo, Wang, Yong · 2021 · Frontiers in Pharmacology
25. Mechanisms of EGFR-TKI-Induced Apoptosis and Strategies Targeting Apoptosis in EGFR-Mutated Non-Small Cell Lung Cancer
    Shigetoshi Nishihara, Toshimitsu Yamaoka, Fumihiro Ishikawa, Kensuke Higuchi, Yuki Hasebe, Ryo Manabe, Yasunari Kishino, Sojiro Kusumoto, Koichi Andō, Yusuke Kuroda et al. · 2022 · Genes
26. Emerging paradigms and recent progress in targeting ErbB in cancers
    Nicolas Stoup, Maxime Liberelle, Nicolas Lebègue, Isabelle VAN SEUNINGEN · 2024 · Trends in Pharmacological Sciences
27. Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, EGFR ‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
    Shun Lü, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu et al. · 2024 · 癌症：英文版
28. Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
    Makoto Nishio, Takashi Seto, Martin Reck, Edward B. Garon, Chao‐Hua Chiu, Kiyotaka Yoh, Fumio Imamura, Keunchil Park, Jin‐Yuan Shih, Carla Visseren‐Grul et al. · 2020 · Cancer Science
29. Survival outcomes and symptomatic central nervous system (CNS) metastasis in EGFR-mutant advanced non-small cell lung cancer without baseline CNS metastasis: Osimertinib vs. first-generation EGFR tyrosine kinase inhibitors
    Yue Zhou, Bo Wang, Jinghan Qu, Fan Yu, Yang Zhao, Shuyan Li, Ya Zeng, Xi Yang, Li Chu, Xiao Chu et al. · 2020 · Lung Cancer
30. Real-world implementation of sequential targeted therapies for EGFR-mutated lung cancer
    Nikolaus Magios, Farastuk Bozorgmehr, Anna‐Lena Volckmar, Daniel N. Kazdal, Martina Kirchner, Felix J.F. Herth, Claus Peter Heußel, Florian Eichhorn, Michael A. Meister, Thomas Muley et al. · 2021 · Therapeutic Advances in Medical Oncology
31. Progress and application of circulating tumor cells in non-small cell lung cancer
    Huizhu Qian, Yue Zhang, Jing Xu, Jing He, Wen Gao · 2021 · Molecular Therapy — Oncolytics
32. A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks
    Chongze Yuan, Haojie Chen, Shiqi Tu, Hsin-Yi Huang, Yunjian Pan, Xiuqi Gui, Muyu Kuang, Xuxia Shen, Qiang Zheng, Yang Zhang et al. · 2021 · Genome biology
33. Brain metastases in patients with oncogenic-driven non-small cell lung cancer: Pros and cons for early radiotherapy
    Jiyun Lee, Myung‐Ju Ahn · 2021 · Cancer Treatment Reviews
34. Mutation-tailored treatment selection in non-small cell lung cancer patients in daily clinical practice
    Elisabeth M. P. Steeghs, Harry J.M. Groen, Ed M. D. Schuuring, Mieke Josepha Aarts, Ronald A.M. Damhuis, Quirinus J.M. Voorham, Marjolijn J. L. Ligtenberg, Katrien Grünberg · 2022 · Lung Cancer
35. Phasing analysis of lung cancer genomes using a long read sequencer
    Yoshitaka Sakamoto, Shuhei Miyake, Miho Oka, Akinori Kanai, Yosuke Kawai, Satoi Nagasawa, Yuichi Shiraishi, Katsushi Tokunaga, Takashi Kohno, Masahide Seki et al. · 2022 · Nature Communications
36. TIAM2 Contributes to Osimertinib Resistance, Cell Motility, and Tumor-Associated Macrophage M2-like Polarization in Lung Adenocarcinoma
    Lu Liang, Hua He, Shiyao Jiang, Yueying Liu, Jingjing Huang, Xiaoyan Sun, Yi Li, Yiqun Jiang, Cong Li · 2022 · International Journal of Molecular Sciences
37. The role of brain radiotherapy for EGFR- and ALK-positive non-small-cell lung cancer with brain metastases: a review
    Valerio Nardone, Caterina Romeo, Emma D’Ippolito, Pierpaolo Pastina, Maria D’Apolito, Luigi Pirtoli, Michele Caraglia, Luciano Mutti, Giovanna Bianco, Antonia Consuelo Falzea et al. · 2023 · La radiologia medica
38. Thinking green: Modelling respirator reuse strategies to reduce cost and waste
    Chu, Jacqueline, Ghenand, Omkar, Collins, Joy, Byrne, James, Wentworth, Adam, Chai, Peter R., Dadabhoy, Farah, Hur, Chin, Traverso, Giovanni · 2021 · BMJ Open
39. Histologic Transformation in EGFR-Mutant Lung Adenocarcinomas: Mechanisms and Therapeutic Implications
    Ranjan Pathak, Victoria Meucci Villaflor · 2021 · Cancers
40. Real-world use of osimertinib for epidermal growth factor receptor T790M-positive non-small cell lung cancer in Japan
    Yuichiro Ohe, Terufumi Kato, Fumikazu Sakai, Masahiko Kusumoto, Masahiro Endo, Yoshinobu Saito, Tomohisa Baba, Masafumi Sata, Ou Yamaguchi, Kei Sakamoto et al. · 2020 · Japanese Journal of Clinical Oncology
41. Efficacy and safety of therapies for EGFR-mutant non-small cell lung cancer with brain metastasis: an evidence-based Bayesian network pooled study of multivariable survival analyses
    Binghao Zhao, Yuekun Wang, Yaning Wang, Wenlin Chen, Lizhou Zhou, Peng Hao Liu, Ziren Kong, Congxin Dai, Yu Wang, Wenbin Ma · 2020 · Aging
42. Knowledge and Practice Patterns Among Pulmonologists for Molecular Biomarker Testing in Advanced Non-small Cell Lung Cancer
    Adam H. Fox, James R. Jett, Upal Basu Roy, Bruce Evan Johnson, Jennifer C. King, Nikki A. Martin, Raymond Uyiosa Osarogiagbon, M. Patricia Rivera, Lauren S. Rosenthal, Robert Allen Smith et al. · 2021 · CHEST Journal
43. High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
    Marta Laganà, Cristina Gurizzan, Elisa Roca, Diego Luigi Cortinovis, Diego Signorelli, Filippo Pagani, Anna Bettini, Lucia Bonomi, Silvia Rinaldi, Rossana Berardi et al. · 2020 · Frontiers in Oncology
44. Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors in Patients With De Novo EGFRT790M-Mutant NSCLC
    Ha-Ram Park, Tae Min Kim, Yusoo Lee, Soyeon Kim, Seongyeol Park, Young Seok Ju, Miso Kim, Bhumsuk Keam, Yoon Kyung Jeon, Dong‐Wan Kim et al. · 2021 · Journal of Thoracic Oncology
45. The evolving role of neurosurgery for central nervous system metastases in the era of personalized cancer therapy
    Philipp Karschnia, Émilie Le Rhun, Michael A. Vogelbaum, Martin J. van den Bent, Stefan Josef Grau, Matthias Preusser, Riccardo Soffietti, Louisa von Baumgarten, Manfred Westphal, Michael Weller et al. · 2021 · European Journal of Cancer
46. Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib
    Kenji Mishiro, Ryuichi Nishii, Izumi Sawazaki, Tomoki Sofuku, Takeshi Fuchigami, Hitomi Sudo, Nurmaya Effendi, Akira Makino, Yasushi Kiyono, Kazuhiro Shiba et al. · 2022 · Journal of Medicinal Chemistry
47. Neoadjuvant and Adjuvant Systemic Therapy for Early-Stage Non-small-Cell Lung Cancer
    James Isaacs, Thomas E. Stinchcombe · 2022 · Drugs
48. CCDC65, a Gene Knockout that leads to Early Death of Mice, acts as a potentially Novel Tumor Suppressor in Lung Adenocarcinoma
    Ziyan Zhang, Ping Xu, Zhe Hu, Zhaojian Fu, Tongyuan Deng, Xiaojie Deng, Lanzhu Peng, Yingying Xie, Lingzhi Long, Dayong Zheng et al. · 2022 · International Journal of Biological Sciences
49. Respiratory and Cardiometabolic Comorbidities and Stages I to III NSCLC Survival: A Pooled Analysis From the International Lung Cancer Consortium
    Miguel García-Pardo, Amy Chang, Sabine Schmid, Mei Dong, M. Catherine Brown, David C. Christiani, Hilary Aurora Tindel, Paul Brennan, Chu Chen, Jie Zhang et al. · 2022 · Journal of Thoracic Oncology
50. A practical approach to the 2022 ESC cardio-oncology guidelines: Comments by a team of experts – cardiologists and oncologists
    Przemysław Leszek, Aneta Klotzka, Stanisław Bartuś, Paweł Burchardt, Anna Malgorzata Czarnecka, Monika Długosz‐Danecka, Marek J. Gierlotka, Hanna Koseła-Paterczyk, Agata Krawczyk‐Ożóg, Tomasz Kubiatowski et al. · 2023 · Kardiologia Polska
51. Population Pharmacokinetics, Pharmacogenomics, and Adverse Events of Osimertinib and its Two Active Metabolites, AZ5104 and AZ7550, in Japanese Patients with Advanced Non-small Cell Lung Cancer: a Prospective Observational Study
    Emi Ishikawa, Yuta Yokoyama, Haruna Chishima, Hidefumi Kasai, Ouki Kuniyoshi, Motonori Kimura, Jun Hakamata, Hideo Nakada, Naoya Suehiro, Naoki Nakaya et al. · 2023 · Investigational New Drugs
52. DNA topoisomerase II inhibition potentiates osimertinib’s therapeutic efficacy in EGFR-mutant non–small cell lung cancer models
    Zhen Chen, Karin A. Vallega, Dongsheng Wang, Zihan Quan, Songqing Fan, Qiming Wang, Ticiana A.B. Leal, Suresh S. Ramalingam, Shi‐Yong Sun · 2024 · Journal of Clinical Investigation
53. Dihydroartemisinin, a potential PTGS1 inhibitor, potentiated cisplatin-induced cell death in non-small cell lung cancer through activating ROS-mediated multiple signaling pathways
    Lianli Ni, Xinping Zhu, Qi Zhao, Yiwei Shen, Lu Tao, Ji Zhang, Han Lin, Weishan Zhuge, Young-Chang Cho, Ri Cui et al. · 2024 · Neoplasia
54. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis
    Susu Zhou, Noriko Kishi, Parissa Alerasool, Nicholas Cole Rohs · 2024 · Targeted Oncology
55. Safety and efficacy of consolidative stereotactic radiotherapy for oligo-residual EGFR-mutant non-small cell lung cancer after first-line third-generation EGFR-tyrosine kinase inhibitors: a single-arm, phase 2 trial
    Yue Zhou, Lin Peng, Fei Liang, Li Chu, Xiao Chu, Xi Yang, Junhua Zhang, Tiantian Guo, Shanshan Jiang, Yechun Pang et al. · 2024 · EClinicalMedicine
56. Overall Survival in EGFR-Mutant Advanced NSCLC Treated With First-Line Osimertinib: A Cohort Study Integrating Clinical and Biomarker Data in the United States
    Joshua K. Sabari, Helena Alexandra Yu, Parthiv Jasvant Mahadevia, Yanfang Liu, Levon Demirdjian, Yen-Hua Chen, Xiayi Wang, Antonio Passaro · 2025 · Journal of Thoracic Oncology
57. FAM64A: A Novel Oncogenic Target of Lung Adenocarcinoma Regulated by Both Strands of miR-99a (miR-99a-5p and miR-99a-3p)
    Keiko Mizuno, Kengo Tanigawa, Nijiro Nohata, Shunsuke Misono, Reona Okada, Shunichi Asai, Shogo Moriya, Takayuki Suetsugu, Hiromasa Inoue, Naohiko Seki · 2020 · Cells
58. Japanese Lung Cancer Society Guidelines for Stage IV NSCLC With EGFR Mutations
    Kiichiro Ninomiya, Shunsuke Teraoka, Yoshitaka Zenke, Hirotsugu Kenmotsu, Yukiko Nakamura, Yusuke Okuma, Akihiro Tamiya, Kaname Nosaki, Masahiro Morise, Keiju Aokage et al. · 2020 · JTO Clinical and Research Reports
59. The Efficacy and Safety of Anlotinib Combined With PD-1 Antibody for Third-Line or Further-Line Treatment of Patients With Advanced Non-Small-Cell Lung Cancer
    Chongya Zhai, Xiaoling Zhang, Lulu Ren, Liangkun You, Qin Pan, Hongming Pan, Weidong Han · 2021 · Frontiers in Oncology
60. Phytochemicals intended for anticancer effects at preclinical levels to clinical practice: Assessment of formulations at nanoscale for non-small cell lung cancer (NSCLC) therapy
    The Hong Phong Nguyen, V. Bharath Kumar, Vinoth Kumar Ponnusamy, T. T. P. Thao, Phuong Tran Nhat, Kathirvel Brindhadevi, Arivalagan Pugazhendhi · 2021 · Process Biochemistry
61. Medicinal herbs and bioactive compounds overcome the drug resistance to epidermal growth factor receptor inhibitors in non‑small cell lung cancer (Review)
    Hiu Lee, Mingjing Meng, Yulong Liu, Tao Su, Hiu Yee Kwan · 2021 · Oncology Letters
62. Brain Metastasis Treatment: The Place of Tyrosine Kinase Inhibitors and How to Facilitate Their Diffusion across the Blood–Brain Barrier
    Eurydice Angeli, Guilhem Bousquet · 2021 · Pharmaceutics
63. Research Progress and Challenges in the Treatment of Central Nervous System Metastasis of Non-Small Cell Lung Cancer
    Bin Wang, Hanfei Guo, Haiyang Xu, Hongquan Yu, Yong Chen, Gang Zhao · 2021 · Cells
64. Impact of Tumor Suppressor Gene Co-Mutations on Differential Response to EGFR TKI Therapy in EGFR L858R and Exon 19 Deletion Lung Cancer
    Jessica A. Hellyer, Maya N. White, Rebecca M. Gardner, Kristen May Cunanan, Sukhmani Kaur Padda, Millie Snigdha Das, Kavitha J. Ramchandran, Joel W. Neal, Heather A. Wakelee · 2021 · Clinical Lung Cancer
65. Integration of liquid biopsy and pharmacogenomics for precision therapy of EGFR mutant and resistant lung cancers
    Jill Kolesar, Keng Hee Peh, Levin Thomas, Gayathri Baburaj, Nayonika Mukherjee, Raveena Kantamneni, Shirley Christabel Lewis, Ananth Pai, Karthik Udupa, Naveena A. N. Kumar et al. · 2022 · Molecular Cancer
66. Retrospective Analysis of Real-World Management of EGFR-Mutated Advanced NSCLC, After First-Line EGFR-TKI Treatment: US Treatment Patterns, Attrition, and Survival Data
    Jorge J. Nieva, Karen L. Reckamp, Danielle M. Potter, Aliki Taylor, Ping Sun · 2022 · Drugs - Real World Outcomes
67. Resistance of Lung Cancer to EGFR-Specific Kinase Inhibitors: Activation of Bypass Pathways and Endogenous Mutators
    Ilaria Marrocco, Yosef Yarden · 2023 · Cancers
68. The clinical development of antibody-drug conjugates for non-small cell lung cancer therapy
    Xinlin Liu, Junwen Deng, Renshuai Zhang, Jiyao Xing, Yudong Wu, Wujun Chen, Bing Liang, Dongming Xing, Jiazhen Xu, Miao Zhang · 2023 · Frontiers in Immunology
69. MERTK Inhibition: Potential as a Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer
    Chao‐Ju Chen, Yu‐Peng Liu · 2021 · Pharmaceuticals
70. Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors
    Bardia Yousefi, Michael Joseph Lariviere, Eric A. Cohen, Thomas H. Buckingham, Stephanie S. Yee, Taylor A. Black, Austin L. Chien, Peter Benjamin Noël, Wei‐Ting Hwang, Sharyn I. Katz et al. · 2021 · Scientific Reports
71. A Phase I Trial of Dasatinib and Osimertinib in TKI Naïve Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer
    Chul Kim, Stephen V. Liu, Jennifer Crawford, Tisdrey Torres, Vincent C. Chen, Jillian Thompson, Ming Tony Tan, Giuseppe Esposito, Deepa Suresh Subramaniam, Giuseppe Giaccone · 2021 · Frontiers in Oncology
72. External validation of the 4C Mortality Score for patients with COVID-19 and pre-existing cardiovascular diseases/risk factors
    Shunsuke Kuroda, Shingo Matsumoto, Takahide Sano, Takeshi Kitai, Taishi Yonetsu, Shun Kohsaka, Sho Torii, Takuya Kishi, Issei Komuro, Ken‐ichi Hirata et al. · 2021 · BMJ Open
73. Sequential afatinib and osimertinib in patients with EGFR mutation-positive NSCLC and acquired T790M: A global non-interventional study (UpSwinG)
    Sanjay Popat, Hyun Ae Jung, Shin Yup Lee, Maximilian Johannes Hochmair, Seung Hyeun Lee, Carles Escriu, Min Ki Lee, Maria Rita Migliorino, Yong Chul Lee, Nicolas Girard et al. · 2021 · Lung Cancer
74. Current Therapeutic Strategies and Prospects for EGFR Mutation-Positive Lung Cancer Based on the Mechanisms Underlying Drug Resistance
    Yukari Tsubata, Ryosuke Tanino, Takeshi Isobe · 2021 · Cells
75. Clonal dynamics of BRAF-driven drug resistance in EGFR-mutant lung cancer
    Diana Schaufler, David Ast, Hannah Lea Tumbrink, Nima Abedpour, Lukas Maas, Ayla E. Schwäbe, Inga Spille, Stefanie Lennartz, Jana Fassunke, Mihaela D. Aldea et al. · 2021 · npj Precision Oncology
76. Complications following novel therapies for non‐small cell lung cancer
    Marcus Skribek, Konstantinos Rounis, Georgios Tsakonas, Simon Ekman · 2022 · Journal of Internal Medicine
77. Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
    Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia‐Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tinè, Giulia Pasello, Paul M Hofman · 2022 · International Journal of Molecular Sciences
78. Early Steps of Resistance to Targeted Therapies in Non-Small-Cell Lung Cancer
    Célia Delahaye, Sarah Figarol, Anne Pradines, Gilles Favre, Julien Mazières, Olivier Calvayrac · 2022 · Cancers
79. P21-activated kinase 2-mediated β-catenin signaling promotes cancer stemness and osimertinib resistance in EGFR-mutant non-small-cell lung cancer
    Yanmei Yi, Pan Li, Yuanfeng Huang, Danyang Chen, Siwen Fan, Jun Wang, Minqiang Yang, Shanshan Zeng, Jin Deng, Xinwu Lv et al. · 2022 · Oncogene
80. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients
    Adam Płużański, Maciej Jerzy Krzakowski, Dariusz Mirosław Kowalski, Rafał Dziadziuszko · 2020 · ESMO Open
81. Immunotherapy in EGFR-Mutant and ALK-Positive Lung Cancer
    Alexander Gavralidis, Justin F. Gainor · 2020 · The Cancer Journal
82. Overcoming Osimertinib Resistance with AKT Inhibition in EGFRm-Driven Non–Small Cell Lung Cancer with PIK3CA/PTEN Alterations
    Ursula Grazini, Aleksandra A. Markovets, Lucy Ireland, Daniel J. O’Neill, Benjamin Phillips, Man Xu, Matthias Pfeifer, Tereza Vaclová, Matthew J. Martin, Ludovic Bigot et al. · 2024 · Clinical Cancer Research
83. Targeting pyruvate dehydrogenase kinase 1 overcomes EGFR C797S mutation-driven osimertinib resistance in non-small cell lung cancer
    Wonyoung Park, Shibo Wei, Chu‐Long Xie, Jung Ho Han, Bosung Kim, Bosung Kim, Jung-Sook Jin, Eun-Sun Yang, Min Kyoung Cho, Dongryeol Ryu et al. · 2024 · Experimental & Molecular Medicine
84. Development and validation of a survival prediction model for patients with advanced non-small cell lung cancer based on LASSO regression
    Yimeng Guo, Li-Hua Li, Keao Zheng, Juan Du, Jingxu Nie, Zanhong Wang, Zhiying Hao · 2024 · Frontiers in Immunology
85. Synthetic Lethal Targeting of CDK12-Deficient Prostate Cancer with PARP Inhibitors
    Jonathan Chou, Troy M. Robinson, Emily A. Egusa, Roshan Lodha, Meng Zhang, Michelle L. Badura, Mane Mikayelyan, Henry M. Delavan, Jason T. Swinderman, Chris Wilson et al. · 2024 · Clinical Cancer Research
86. A clinical review on third and fourth generation EGFR tyrosine kinase inhibitors for the treatment of non-small cell lung cancer
    Chandrakant Gawli, Chandragouda Raosaheb Patil, Harun Patel · 2025 · Bioorganic & Medicinal Chemistry
87. Strategies Beyond 3rd EGFR‐TKI Acquired Resistance: Opportunities and Challenges
    Xuexue Zhou, Liang Zeng, Zhe Huang, Zhaohui Ruan, Huan Yan, Chun Zou, Shidong Xu, Yongchang Zhang · 2025 · Cancer Medicine
88. Is there a role for dacomitinib, a second-generation irreversible inhibitor of the epidermal-growth factor receptor tyrosine kinase, in advanced non-small cell lung cancer?
    Cecilia Bergonzini, Alessandro Leonetti, Marcello Tiseo, Elisa Giovannetti, Godefridus J. Peters · 2020 · Expert Opinion on Pharmacotherapy
89. erbB in NSCLC as a molecular target: current evidences and future directions
    Marzia Del Re, Federico Cucchiara, Iacopo Petrini, Stefano Fogli, Antonio Passaro, Stefania Crucitta, Ilaria Attili, Filippo de Marinis, Antonio Chella, Romano Danesi · 2020 · ESMO Open
90. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway
    Fang Yang, Shuai Zhang, Qingwei Meng, Fengrui Zhou, Bo Pan, Fang Liu, Yan Yu · 2021 · Pulmonary Pharmacology & Therapeutics
91. Neutrophil-to-Lymphocyte Ratio Is a Predictive Biomarker in Patients with Epidermal Growth Factor Receptor (EGFR) Mutated Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Tyrosine Kinase Inhibitor (TKI) Therapy
    Nicole K. Yun, Sherin Juliet Rouhani, Christine M. Bestvina, Ethan Matthew Ritz, Brendan A. Gilmore, Imad Tarhoni, Jeffrey Allen Borgia, Marta Batus, Philip Bonomi, Mary J. Fidler · 2021 · Cancers
92. Fighting tertiary mutations in EGFR-driven lung-cancers: Current advances and future perspectives in medicinal chemistry
    Laura Scalvini, Riccardo Castelli, Silvia La Monica, Marcello Tiseo, Roberta R Alfieri · 2021 · Biochemical Pharmacology
93. The landscape of immune checkpoint inhibitor therapy in advanced lung cancer
    Chengdi Wang, Jingwei Li, Qiran Zhang, Jiayang Wu, Yuxuan Xiao, Lujia Song, Hanlin Gong, Yalun Li · 2021 · BMC Cancer
94. First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study (HOT2002)
    Gaku Yamamoto, Hajime Asahina, Osamu Honjo, Toshiyuki Sumi, Atsushi Nakamura, Kenichiro Ito, Hajime Kikuchi, Fumihiro Hommura, Ryoichi Honda, Keiki Yokoo et al. · 2021 · Scientific Reports
95. FGFR Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)
    Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, Suyog Jain, Steve Olsen, Lior Soussan‐Gutman, Taly Ben-Shitrit, Addie Dvir, Hovav Nechushtan, Nir Peled et al. · 2022 · Journal of Clinical Medicine
96. Driver mutation characteristics of phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) in advanced non-small cell lung cancer
    Sameh Daher, Alona Zer, Roi Tschernichovsky, Rinat Yacobi, Iris Barshack, Shani Tsabari, Yakir Rottenberg, Aviad Zick, Teodor Gottfried, Anastasiya Lobachov et al. · 2023 · Lung Cancer
97. A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations
    L. Villaruz, X. Wang, Erin Marie Bertino, Linping Gu, Scott Joseph Antonia, Timothy Francis Burns, Jeffrey Melson Clarke, Jeffrey Crawford, Terry L. Evans, David Friedland et al. · 2023 · ESMO Open
98. HERTHENA-Lung01: A Phase II Study of Patritumab Deruxtecan (HER3-DXd) in Previously Treated Metastatic EGFR -mutated NSCLC
    Helena Alexandra Yu, James Chih‐Hsin Yang, Hidetoshi Hayashi, Yasushi Goto, Enriqueta Felip, Martin Reck, Michele Vigliotti, Qian Dong, Frederique Cantero, Pang‐Dian Fan et al. · 2023 · Future Oncology
99. Evolutionary proteogenomic landscape from pre-invasive to invasive lung adenocarcinoma
    Yang Zhang, Fangqiu Fu, Qiao Zhang, Lingling Li, Hui Liu, Chaoqiang Deng, Qianqian Xue, Yue Zhao, Wenrui Sun, Han Han et al. · 2024 · Cell Reports Medicine
100. A narrative review of the role of common EGFR mutations in pathogenesis and treatment of non-small-cell lung carcinoma
     Mansi Sharma, Dharmishtha Ashis Basu, Shrinidhi Nathany, B. P. Amrith, Ullas Batra · 2022 · Cancer Research Statistics and Treatment